These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hypertension, hyperlipidemia, and renal damage. Keane WF; Kasiske BL; O'Donnell MP; Kim Y Am J Kidney Dis; 1993 May; 21(5 Suppl 2):43-50. PubMed ID: 8494018 [TBL] [Abstract][Full Text] [Related]
4. [New recognition of a role of dyslipidemia and lipid-lowering treatment in pathogenesis of renal disease]. Li XW; Li H Zhonghua Nei Ke Za Zhi; 2004 Dec; 43(12):881-2. PubMed ID: 15730728 [No Abstract] [Full Text] [Related]
5. Treating dyslipidemia to slow the progression of chronic renal failure. Palmer BF; Alpern RJ Am J Med; 2003 Apr; 114(5):411-2. PubMed ID: 12714133 [No Abstract] [Full Text] [Related]
6. [Kidney and statins]. Moulin B; Caillard S Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 2):121-7. PubMed ID: 11240414 [TBL] [Abstract][Full Text] [Related]
7. [Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia]. Restrepo Valencia CA; Cruz J Nefrologia; 2008; 28(1):61-6. PubMed ID: 18336133 [TBL] [Abstract][Full Text] [Related]
8. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. Owada A; Suda S; Hata T Am J Med; 2003 Apr; 114(5):347-53. PubMed ID: 12714122 [TBL] [Abstract][Full Text] [Related]
9. Progression of renal damage in glycogen storage disease type I is associated to hyperlipidemia: a multicenter prospective Italian study. Melis D; Cozzolino M; Minopoli G; Balivo F; Parini R; Rigoldi M; Paci S; Dionisi-Vici C; Burlina A; Andria G; Parenti G J Pediatr; 2015 Apr; 166(4):1079-82. PubMed ID: 25641239 [TBL] [Abstract][Full Text] [Related]
10. Statins and renal function. Elisaf M; Mikhailidis DP Angiology; 2002; 53(5):493-502. PubMed ID: 12365855 [TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia. Dujovne CA; Moriarty PM Clin Ther; 1996; 18(3):392-410; discussion 391. PubMed ID: 8829016 [TBL] [Abstract][Full Text] [Related]
12. Management of blood lipid abnormalities in coronary heart disease patients. Kuo PT Clin Cardiol; 1989 Oct; 12(10):553-60. PubMed ID: 2680196 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of cardiovascular injury in renal disease. Rabelink TJ; Stroes ES; Koomans HA Blood Purif; 1996; 14(1):67-74. PubMed ID: 8718568 [TBL] [Abstract][Full Text] [Related]
15. Treatment of hyperlipidemia in human renal disease. D'Amico GD; Gentile MG Miner Electrolyte Metab; 1993; 19(3):196-204. PubMed ID: 8232107 [TBL] [Abstract][Full Text] [Related]
16. Lipoprotein abnormalities in the progression of renal disease. Brouhard BH; Cressman MD; Irwin KC; Stowe NT Cleve Clin J Med; 1990 Oct; 57(7):599-604. PubMed ID: 2225443 [TBL] [Abstract][Full Text] [Related]
17. Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. Duntas L; Kolovou G Future Cardiol; 2011 Mar; 7(2):137-44. PubMed ID: 21453018 [No Abstract] [Full Text] [Related]
19. Assessment and management of vascular disease risk in patients with chronic kidney disease. Brown WV; Bakris G; Lerma E; Chertow G J Clin Lipidol; 2011; 5(4):251-60. PubMed ID: 21784369 [No Abstract] [Full Text] [Related]
20. Optimization of hypolipidemic and antiplatelet treatment in the diabetic patient with renal disease. Trovati M; Cavalot F J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S12-20. PubMed ID: 14684665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]